Novartis: Meningococcal Infections trials

The registry lists 60 Meningococcal Infections studies with Novartis as lead sponsor. 0 are open to participants now and 48 have results posted.

Phase 2 24Phase 3 30Phase 4 6No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects.CompletedNCT02141516Phase 3Results posted
• Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy AdolescentsCompletedNCT02140762Phase 2Results posted
• Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy ToddlersCompletedNCT01994629Phase 2Results posted
• Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180)CompletedNCT01992536Phase 2Results posted
• Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years.CompletedNCT01973218Phase 3Results posted
• A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive.CompletedNCT01911221Phase 3Results posted
• Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster DoseCompletedNCT01823536Phase 4Results posted
• Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Children, Adolescents and Adults in RussiaCompletedNCT01725217Phase 3Results posted
• Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1CompletedNCT01717638Phase 3Results posted
• A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk AdultsCompletedNCT01478347Phase 3Results posted
• A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in AdultsCompletedNCT01466387Phase 3Results posted
• Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate VaccineCompletedNCT01453348Phase 3Results posted
• Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy ToddlersCompletedNCT01434680Phase 2Results posted
• Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 YearsCompletedNCT01423084Phase 3Results posted
• Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY Combination Vaccine in Adolescents Who Previously Received the Same Study VaccinesCompletedNCT01367158Phase 2Results posted
• Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate VaccineCompletedNCT01345721Phase 3Results posted
• A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 YearsCompletedNCT01339923Phase 3Results posted
• A Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of MenACWY in Adolescents and Adults in KoreaCompletedNCT01274897Phase 3Results posted
• Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young AdultsCompletedNCT01272180Phase 2Results posted
• Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of LifeCompletedNCT01214837Phase 3Results posted
• Assessment of Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10CompletedNCT01148524Phase 2/3Results posted
• One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of AgeCompletedNCT01139021Phase 3Results posted
• Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received One or Four Doses of the Same VaccineCompletedNCT01027351Phase 2Results posted
• Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received Three Doses of the Same VaccineCompletedNCT01026974Phase 2Results posted
• A Study to Evaluate the Persistence and Immune Response to a Booster Dose of MenACWYCompletedNCT01018732Phase 2Results posted
• A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 MonthsCompletedNCT01000311Phase 3Results posted
• Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12CompletedNCT00944034Phase 2/3Results posted
• Safety and Immunogenicity in Dose-Ranging and Formulation-Finding Meningococcal B (MenB) Vaccine Study in 2-month-old InfantsCompletedNCT00937521Phase 2Results posted
• Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy ToddlersCompletedNCT00847145Phase 3Results posted
• Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy InfantsCompletedNCT00806195Phase 3Results posted
• Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization SchedulesCompletedNCT00721396Phase 2Results posted
• Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination SchedulesCompletedNCT00661713Phase 2/3Results posted
• Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy InfantsCompletedNCT00657709Phase 3Results posted
• Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy ToddlersCompletedNCT00626327Phase 3Results posted
• Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy ChildrenCompletedNCT00616421Phase 3Results posted
• Evaluation of Meningococcal ACWY Immune Response in Children Aged 40 and 60 MonthsCompletedNCT00601731Phase 2Results posted
• Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk AdultsCompletedNCT00560313Phase 2Results posted
• B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy InfantsCompletedNCT00488683Phase 2Results posted
• A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In InfantsCompletedNCT00474526Phase 3Results posted
• A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Healthy AdultsCompletedNCT00474487Phase 3Results posted
• A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and AdultsCompletedNCT00450437Phase 3Results posted
• Safety, Tolerability and Immunogenicity of Two Different Formulations of Meningococcal B Recombinant Vaccine, When Administered to Healthy InfantsCompletedNCT00433914Phase 2Results posted
• Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy StudyCompletedNCT00381615Phase 2Results posted
• Immunogenicity and Safety of the Concomitant Administration of a Tdap Vaccine and Meningococcal ACWY Conjugate Vaccine in Healthy Subjects Aged 11-25 YearsCompletedNCT00329901Phase 3Results posted
• Safety and Immunogenicity of Meningococcal ACWY Conjugate Versus Polysaccharide Vaccine in Children 2 to 10 Years of AgeCompletedNCT00329849Phase 3Results posted
• Study of the Safety and Immune Response of a Meningococcal Conjugate Vaccine Administered to Healthy AdolescentsCompletedNCT00262041Phase 2Results posted
• Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy ChildrenCompletedNCT00262028Phase 2Results posted
• Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy InfantsCompletedNCT00262002Phase 2Results posted
• Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects 2 Years of Age and OlderWithdrawnNCT01705379
• Safety of MenACWY-CRM Vaccination in AdolescentsCompletedNCT01452464
• Safety Surveillance of MenACWY-CRM Vaccine in ChildrenCompletedNCT01452438
• Immunogenicity and Safety of Different rMenB Plus MenACWY Formulations in AdolescentsCompletedNCT01210885Phase 2
• Persistence of Antibody Response to N. Meningitidis Group C in ChildrenCompletedNCT00316654Phase 4
• Immunogenicity, Safety, Tolerability and Ability to Prime for Memory of Meningococcal C Conjugate Vaccine in Healthy ChildrenCompletedNCT00311415Phase 3
• Persistence of Antibodies and Kinetics of B Cell Response in Healthy Children After Vaccination With MCC VaccineCompletedNCT00310713Phase 4
• Kinetics of B Cell Response in Infants Menjugate VaccinationCompletedNCT00310700Phase 4
• Persistence of Immune Response After Vaccination With MCCCompletedNCT00310687Phase 4
• Immunogenicity, Safety and Tolerability, of Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Premature and Non Premature Children of 3 Months of AgeCompletedNCT00310674Phase 3
• Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of AgeCompletedNCT00310635Phase 4
• Study of the Safety and Immune Response of Two Serogroup B Meningococcal Vaccines Administered to Healthy AdolescentsCompletedNCT00297817Phase 2